Format

Send to

Choose Destination
Diagn Microbiol Infect Dis. 2015 Apr;81(4):283-9. doi: 10.1016/j.diagmicrobio.2014.12.009. Epub 2014 Dec 30.

In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program.

Author information

1
JMI Laboratories, North Liberty, IA 52317, USA. Electronic address: robert-flamm@jmilabs.com.
2
JMI Laboratories, North Liberty, IA 52317, USA.
3
Pfizer Inc, Collegeville, PA 19426, USA.
4
JMI Laboratories, North Liberty, IA 52317, USA; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
5
JMI Laboratories, North Liberty, IA 52317, USA; Tufts University School of Medicine, Boston, MA 02111, USA.

Abstract

The 2013 LEADER surveillance program monitored the in vitro activity of linezolid and comparator agents against Gram-positive bacteria at 60 medical centers in the United States. A total of 7183 pathogens were contributed from 6 predetermined pathogen groups. The groups were Staphylococcus aureus, coagulase-negative staphylococci, enterococci, Streptococcus pneumoniae, β-hemolytic streptococci, and viridans group streptococci. The MIC90 value for each of the 6 pathogen groups was 1 μg/mL. Susceptibility of "all organisms" to linezolid was 99.83%. Only 12 isolates (2 S. aureus, 3 Staphylococcus epidermidis, 1 Streptococcus sanguinis, 5 Enterococcus faecium, and 1 Enterococcus faecalis) were nonsusceptible to linezolid (0.17%). Three of these (2 S. aureus and 1 E. faecium) harbored the cfr resistance mechanism. The findings indicate that linezolid activity remains stable, although there are examples of clonal dissemination within several monitored institutions.

KEYWORDS:

LEADER; Linezolid; Oxazolidinones

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center